{"id":386726,"date":"2020-11-23T08:33:30","date_gmt":"2020-11-23T13:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386726"},"modified":"2020-11-23T08:33:30","modified_gmt":"2020-11-23T13:33:30","slug":"ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/","title":{"rendered":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not<\/li>\n<li style=\"text-align:left\">AB201 is the only novel compound being developed for COVID Associated Coagulopathy<\/li>\n<li style=\"text-align:left\">Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December<\/li>\n<li style=\"text-align:left\">Topline trial data anticipated Q2 2021<\/li>\n<\/ul>\n<p align=\"both\">WESTMINSTER, Colo., Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cwf2QRJ_A02eUSE2g5gKUXcsOM9NfvGKgBoDqFdWbXyJshinC7BGLlyKGLc-T9igs0NV0edhsm78ho9Fyp1BQQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ARCA biopharma, Inc.<\/a> (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nB9nuaQ65HccEzfcKHmK3Gt5gYJcDh8VJH7EHxTyONoGGCPtKU9ZxBiQRpnHynowSAhJ0gZ-XdqpDh-TVZdFLSiQvMOA9dk5tbmIdOBMUHI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">U.S. Food and Drug Administration<\/a> (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in the second quarter of 2021.<\/p>\n<p align=\"both\">According to the FDA\u2019s Fast Track Guidance document, Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.<\/p>\n<p align=\"both\">\u201cFast Track designation for the AB201 development program is an important acknowledgement of the critical need for treatments for hospitalized COVID-19 patients, whether effective vaccines are approved and available or not,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zgkTFzFcx5EZaNPxg7vIg5x4a5BWYJEpS1p2uAYj4lUVWAvSOkO3uaerQGMF3OyZVRgnakBR4OJ3DEsNKUKB0LUo7XPd-F2Yh-7Pb1I0Wlp400gECh-1v0GA4UbGRPpl\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr. Michael Bristow<\/a>, ARCA\u2019s President and Chief Executive Officer, who is also an <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OCRvggmYUXElaaNEILNh-W-q-tHPdtFK073aGKsrYTJC7svw6Pk8E_UAcnuSiug6oBqqRUxHgxZ6Mtgn7x_lqOHFYUwCwdYrHEGqvFUKikNyDK45UT3RdzBMDPWkl7qFBihnrUYhBkhuGso71LBwuQ9PVF7sQF4BsA8_Bm1iZ0rdhGDlumDRJ1HTJyyIuQt4wayZXqp6MbFq45_v1NFxr1IKkIgU0D3FOKUvb6vzlaw7Rd8wWWbIZoctTmhj-rmKAm9i07SLk9Gh1thQjRjXwK-8DwO2tj1iGXzXlfCJm64=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">American Heart Association (AHA) funded COVID-19 investigator<\/a>. \u201cWe believe AB201\u2019s combination of anticoagulant, anti-inflammatory and antiviral effects may favorably impact clinical recovery of patients hospitalized with COVID-19 and look forward to beginning the ASPEN-COVID-19 trial to evaluate AB201\u2019s potential efficacy in this patient population.&#8221;<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5zn9hrtlZI0vtasoU8T3YGbTolQK-Fp9dNWB0SiyzKHqHqSYi01yn4wuGk7yAinHclmznsR1_5kHIdmF01-GtgYf0tl9OBpj8QHgIZ1hLrc33UaW46tAaLCnX6_f34Mt\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Fast Track<\/a> drug development designation is included in the FDA Modernization Act of 1997 (FDAMA) as a formal process to enhance interactions with the FDA during drug development. A drug development program with Fast Track designation would be eligible for consideration for some or all of the following programs for expediting development and review: scheduled meetings to seek FDA input into development plans, priority review of the New Drug Application (NDA), the option of submitting portions of an NDA prior to submission of the complete application and potential accelerated approval. ARCA believes that AB201 is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation.<\/p>\n<p align=\"both\">\n        <strong>About <\/strong><br \/>\n        <strong>AB201<\/strong><br \/>\n        <br \/>AB201 is a small recombinant protein being developed as a potential treatment for RNA virus-associated diseases, initially focusing on COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives AB201 a combination of anticoagulant, anti-inflammatory and antiviral properties, and therefore the potential to be effective in addressing the impact of viral infections from multiple pathways. AB201 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including in clinical studies for prevention of venous and arterial thrombosis, where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system and other aspects of the immune response, resulting in serious complications. Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that AB201 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating AB201 as a treatment for COVID-19 and other RNA virus associated diseases.<\/p>\n<p align=\"both\">\n        <strong>About ARCA biopharma<\/strong><br \/>\n        <br \/>ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing Gencaro<sup>TM<\/sup> (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential pharmacogenetic treatment for atrial fibrillation in patients with heart failure. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JzsPLnHrx5OyDq2GmAZWqtYAg1U7bnkvaKyWLl24dj4jz3SVeirce2msh253XnEb1gA0786lOFWpXaWMdAG6UA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.arcabio.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GyBdmmxn9WeLgg-z68-FBsCBFMBhYpASihaMo_ADfhNOciPG_64rrS6DHk-9FyHxrU6atK9ern5bd-d9R1R9w2dL-i_8ZsM6XfEhWGcvgpRAIHbDy-NEVF4FgUAUSQTJ\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"both\">\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>\n        <em>This press release contains &#8220;forward-looking statements&#8221; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding<\/em><br \/>\n        <em>potential <\/em><br \/>\n        <em>future <\/em><br \/>\n        <em>development plans for <\/em><br \/>\n        <em>AB201<\/em><br \/>\n        <em>, the <\/em><br \/>\n        <em>expected features and characteristics of <\/em><br \/>\n        <em>AB201<\/em><br \/>\n        <em>,<\/em><br \/>\n        <em>AB201\u2019<\/em><br \/>\n        <em>s potential to treat <\/em><br \/>\n        <em>COVID-19<\/em><br \/>\n        <em>, CAC<\/em><br \/>\n        <em> or <\/em><br \/>\n        <em>any other RNA virus associated disease<\/em><br \/>\n        <em>,<\/em><br \/>\n        <em>whether AB201 <\/em><br \/>\n        <em>is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation<\/em><br \/>\n        <em>and <\/em><br \/>\n        <em>future treatment options for patients with<\/em><br \/>\n        <em> COVID-19<\/em><br \/>\n        <em>. <\/em><br \/>\n        <em>Such statements are based on management&#8217;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA\u2019s financial resources and whether they will be sufficient to meet its business objectives and operational requirements;<\/em><br \/>\n        <em>ARCA <\/em><br \/>\n        <em>may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of <\/em><br \/>\n        <em>AB201 <\/em><br \/>\n        <em>or t<\/em><br \/>\n        <em>o otherwise continue operations in the future;<\/em><br \/>\n        <em> results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA\u2019s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and <\/em><br \/>\n        <em>described in more detail in ARCA\u2019s filings with the Securities and Exchange Commission, including without limitation ARCA\u2019s annual report on Form 10-K for the year ended <\/em><br \/>\n        <em>December<\/em><br \/>\n        <em>\u00a0<\/em><br \/>\n        <em>31<\/em><br \/>\n        <em>,<\/em><br \/>\n        <em>\u00a0<\/em><br \/>\n        <em>201<\/em><br \/>\n        <em>9<\/em><br \/>\n        <em>, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"both\">\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Derek Cole<br \/>720.940.2163<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gPonHTZAiOgpEviGvagxgv_Jm8GPCI3m_-iriNc2rKf-vIknceZOs2g31IDfAE1MorqHiK7AOPPbmOAGNoR7b4TZsBoMH-oVnclEtNzybBA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">derek.cole@arcabio.com<\/a><\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lulm0vnbsbXuU7w_Oa-P2_RlMk8y27uYMZWE3iDrbOyuoWhD0QCAOEj8aqRoBwqk-tJh_3a-SBFoSfZA7hs4GMZs0nXiZj9qKhZhC2dmEQ3hu0oxL474uYLbaKj7i3wLwwPpcbS0p9m6kiRdceyLKDQdvSwIF4SQ1u6DnHXJ-gKRTTKcNEYZ4O1vnclcz7BqaAdimC6UFU_b8RFaYLN3UgBmh9pnxX5_4lpJxEWyLULih8wd0P8KIbLm6EVoAeU_acW5aHAjvsQslsF7_Z-hFw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/af496e97-20da-420a-bf93-e51b3a3ed740<\/a>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0b08689f-3030-4998-b168-efcef14da5bc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not AB201 is the only novel compound being developed for COVID Associated Coagulopathy Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December Topline trial data anticipated Q2 2021 WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386726","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not AB201 is the only novel compound being developed for COVID Associated Coagulopathy Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December Topline trial data anticipated Q2 2021 WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with &hellip; Continue reading &quot;AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation\",\"datePublished\":\"2020-11-23T13:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/\"},\"wordCount\":1024,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/\",\"name\":\"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\",\"datePublished\":\"2020-11-23T13:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/","og_locale":"en_US","og_type":"article","og_title":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk","og_description":"Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not AB201 is the only novel compound being developed for COVID Associated Coagulopathy Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December Topline trial data anticipated Q2 2021 WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with &hellip; Continue reading \"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation","datePublished":"2020-11-23T13:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/"},"wordCount":1024,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/","name":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=","datePublished":"2020-11-23T13:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDY2OCMzODM5MzE3IzIwMDkxNDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-s-fda-fast-track-designation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386726"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386726\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}